<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta name="generator" content="Hugo 0.18.1" />


<title>Precision Medicine &amp; Clinical Pharmacology - A Hugo website</title>
<meta property="og:title" content="Precision Medicine &amp; Clinical Pharmacology - A Hugo website">



  







<link rel="stylesheet" href="../../../../css/fonts.css" media="all">
<link rel="stylesheet" href="../../../../css/main.css" media="all">



  </head>
  <body>
    <div class="wrapper">
      <header class="header">
        <nav class="nav">
  <a href="../../../../" class="nav-logo">
    <img src="../../../../images/logo.png"
         width="50"
         height="50"
         alt="Logo">
  </a>

  <ul class="nav-links">
    
    <li><a href="../../../../about/">About</a></li>
    
    <li><a href="https://github.com/rstudio/blogdown">GitHub</a></li>
    
    <li><a href="https://twitter.com/rstudio">Twitter</a></li>
    
  </ul>
</nav>

      </header>


<main class="content" role="main">

  <article class="article">
    
    <span class="article-duration">6 min read</span>
    

    <h1 class="article-title">Precision Medicine &amp; Clinical Pharmacology</h1>

    
    <span class="article-date">0001/01/01</span>
    

    <div class="article-content">
      

<h1 id="2016-kscpt">2016 KSCPT</h1>

<p><img src="http://i.imgur.com/io9QIQDh.jpg" alt="Materials" /></p>

<h2 id="opening-remark">Opening Remark</h2>

<ul>
<li>Yil-Seob Lee (president of KSCPT)</li>
</ul>

<h2 id="first-session">First Session</h2>

<ul>
<li>Chair : Deborah Chee(KoNECT)</li>
</ul>

<h3 id="13-20-14-00-precision-medicine-a-clinical-pharmacological-perspective">13:20~14:00 Precision Medicine: A Clinical Pharmacological Perspective</h3>

<ul>
<li>Speaker: <a href="https://en.wikipedia.org/wiki/Munir_Pirmohamed">Munir Pirmohamed</a> (University of Liverpool, UK)</li>
<li>Fava beans - Favism G6PD deficiency - withrawal of antimalarials</li>
<li>2015 Obama Precision Medicine $215m / 2016 China $8b</li>
<li>Phenotypic definition(current standard) - Molecular definition (disease stratification) - Drug variability</li>
<li>Mandatory genomic testing - EMA SmPC</li>
<li>Pharmacogenomics Journal (2015) 1-10</li>
<li>Crizotinib vs CTx in advanced ALK+ lung cancer (NEJM 2013)</li>
<li>Novel trial design (Nature 2015)

<ol>
<li>Umbrella trial (single tumor - multiple arm - multiple drugs)</li>
<li>Basket study</li>
</ol></li>
<li>Support of humen genetic evidence for approved drug indication (Nature Genetics)</li>
<li>Sclerosteosis - skeletal overgrowth and syndactyly, AR , mutations in SOST gene - target sclerostin

<ul>
<li>anti-sclerostin Ab (ROMOSOZUMAB, BLOSOZUMAB) - bone density increase - mouse</li>
</ul></li>
<li>New cardiovascular targets

<ul>
<li>PCSK9 - GOF-&gt;LDL-C increase &amp; CVD</li>
<li>ANGPTL4</li>
</ul></li>
<li>HLA-genotype and carbamazepine-induced cutaneous ADR: systemic review (CPT,2012)

<ul>
<li>ITCH (Drug hypersensitivity)</li>
<li>Phase I, II - very strong association (Manhattan plot) - GWAS - ALK(germline polymorphism-&gt; T cell expansion)</li>
<li>SJS GWAS (Genin 2011) <a href="http://www.ncbi.nlm.nih.gov/pubmed/21801394">http://www.ncbi.nlm.nih.gov/pubmed/21801394</a></li>
<li>Skin, Liver</li>
<li>CBZ-induced hypersensitivity vs CBZ-tolerant patients</li>
<li>HLA-A*31:01(thirtyone o one)</li>
</ul></li>
<li>HLA and ADR</li>
<li>The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. (2016) <a href="http://www.ncbi.nlm.nih.gov/pubmed/26478982">http://www.ncbi.nlm.nih.gov/pubmed/26478982</a></li>
<li>Somatic genomes -&gt; microbiome is also important</li>
<li>Digoxin and antibiotics (1981, NEJM) -&gt; (2013 Science) Cardiac drug inactivation by human gut bacteria</li>
<li>Microbiome and Cancer Immunotherapy - Snyder, Science Nov 2015</li>
<li>Two books introduced.

<ol>
<li>Prescription for nhs</li>
<li>clinical pharma dynamic medical specialty</li>
</ol></li>
</ul>

<h3 id="14-00-14-30-the-role-of-pharmacogenomics-in-drug-development-regulatory-review-and-clinical-practice">14:00~14:30 The role of pharmacogenomics in drug development, regulatory review and clinical practice</h3>

<ul>
<li>Speaker: Shiew-Mei Huang (North Potomac, MD, USA)</li>
<li>CPIC (Clinical pharmacogenetics guidelines)</li>
<li>IFNL3(IL28B) HCV treatment Favorable response = 77% Asian (Genotype CC)</li>
<li>Paving the way for Personalized Medicine (Oct 2013)</li>
<li>Avacavir HLA-B*5701 (RCT) Utility of pharmacogenetic tests</li>
<li>Munir mentioned - CBZ &amp; HLA-B*1502</li>
<li>ASCO meeting - CTx vs Targeted therapy - Umbrella study</li>
<li>Drug labeling &ldquo;FDA-approved test&rdquo;</li>
<li>XALKORI - Crizotinib and ALK</li>
<li>CPT Feb 2016 - Precision Medicine , &ldquo;Companion Diagnostics&rdquo; Something unique to conduct , &ldquo;Complementary diagnostics&rdquo;</li>
<li>Eliglustat and CYP2D6 , Drug labeling</li>
<li>Center for Device</li>
<li>Integral to the future of personalized or precision medicine</li>
<li>NGS</li>
<li>PrecisionFDA initiative</li>
<li>23andMe - Drug response , Confidence</li>
<li>Cleared or approved FDA</li>
<li>CLIA-certified laboratory</li>
</ul>

<h4 id="my-question">My Question</h4>

<ul>
<li>One NGS - individual test to is there a review of all-in-one Test in progress?</li>
</ul>

<h3 id="14-30-15-00-the-liver-gut-microbiota-axis-modulates-inter-individual-variability-in-xenobiotic-disposition-and-toxicology">14:30~15:00 The Liver-Gut Microbiota Axis Modulates Inter-Individual Variability in Xenobiotic Disposition and Toxicology</h3>

<ul>
<li>Speaker: Eric Chun Yong Chan (National University of Singapore)</li>
<li>Liver - major organ for disposition and detoxification</li>
<li>60% (explanble) vs 40% (how about this?) - superorganism</li>
<li>400 different species (~1.5kg)</li>
<li>Haiser (2012, Science) Gut microbe - drug, host interaction</li>
<li>TOC: 1 DMD paper ,  2 in-house project</li>
<li>DMD - reduction, hydrolysis</li>
<li>absorption - simvastatin - poor responder, average, good 10% 80% 10%

<ul>
<li>OATP1B1 in liver and intestine</li>
<li>Possibility of competition between simvastatin and bile acids for hepatic uptake by transporter</li>
<li>antibiotics - nitro-reduction by gut microbiota inhibition</li>
<li>Therapeutic fficacy - DDI</li>
</ul></li>
<li>PCA analysis PNAS 2009 - significant differences in concentration</li>
<li>PNAS 2009  inverse corr - p-cresol &lt;-&gt; AAP</li>
<li>2nd part - Tacrine - first drug approved for AD. Toxicological manifestation - increased AST/ALT</li>
<li>Interindividual variability. why?</li>
<li>Tacrine metabolism - hydroxylation / glucuronide</li>
<li>mitochondrial toxicity and hypoxia-reoxygenation</li>
<li>part I~V</li>
<li>Tacrine-induced transaminitis</li>
<li>EXT - CMax,AUC high why? - phase II metabolite?</li>
<li>host gene - mRNA</li>
<li>GC/TO</li>
<li>PCA analysis principal component analysis</li>
<li>NORMAL Lactobacillus</li>
<li>EXT Bacteriode Blautia</li>
<li>Metagenome level</li>
<li>Liver  - Tacrine-&gt; TacrineNGlucuronide</li>
</ul>

<h2 id="second-session">Second Session</h2>

<ul>
<li>Chair : Yong-Bok Lee(Chonnam National University)</li>
</ul>

<h3 id="15-20-15-50-the-role-of-stem-cells-in-discovery-and-validation-of-pharmacogenomic-markers">15:20~15:50 The role of stem cells in discovery and validation of pharmacogenomic markers</h3>

<ul>
<li>Speaker : Eileen Dolan (The University of Chicago, USA)</li>
<li>Ototoxicity, CTx Toxicity - hearing loss, peripheral neuropathy</li>
<li>dose-limiting toxicity - platinum, taxanes, vinca, epothilones, bortezomib</li>
<li>numbness, tingling, burning/stabbing pain</li>
<li>partially , can be permanent</li>
<li>Duloxetine - SNRI - CIPN</li>
<li>pharmacogenomic studies - optimal model - testicular cancer -</li>
<li>platinating agents</li>
<li>CIPN - &gt;300mg/m2, dorsal root g. cell apoptosis, affects large neurons, axonal projections</li>
<li>CTCAE of CIPN, patient-reported measures preferred (CIPN EORTC-CPIN20)</li>
<li>PCA analysis</li>
<li>age, smoking</li>
<li>GWAS - CIPN6 -&gt; CAMTA1, RGS, WDR1, MAPK9, COA1, ILR2A</li>
<li>Polygenic architecture</li>
<li>PIPN : ECOG: rs3125923</li>
<li>Stem cells - problems - identifying, priortizing</li>
<li>cell-based PD analysis</li>
<li>iPSC technology in PGx, CRISPR</li>
<li>Neuronal measurements - total outgrowth processes, process length, branches, cell body area</li>
<li>C, P, 5FU, Bortezomib, Vinc, Thalidomide</li>
<li>inhibition of neurite outgrowth</li>
<li>VIN - GWAS 2000 patients</li>
<li>CEP72 - microtubules assembly, TT allele - susceptible -&gt; lower CEP72 mRNA expression</li>
<li>knockdown of CEP72 in iPCSC -&gt; enhancing sensitivity to vincristine</li>
</ul>

<h4 id="questions-neurite-outgrowth">Questions - neurite outgrowth</h4>

<ul>
<li>Neurons- mature enough?</li>
</ul>

<h3 id="15-50-16-20-pharmacogenomics-and-epigenomics">15:50~16:20 Pharmacogenomics and Epigenomics</h3>

<ul>
<li>Speaker: Matthias Schwab (IKP Stuttgart, Germany)</li>
<li>Prognostic predictors</li>
<li>Genetic make-up</li>
<li>135 FDA-approved drugs with labeled pharmacogenomic information (2015-05-20)</li>
<li>top 30 drugs with pharmacogenetic risk (w/ or w/o high-risk diplotype for gene)</li>
<li>Genomics, proteomics metabolomics, microbiomics</li>
<li>Genome Medicine 2016 (Auffray, Schwab)</li>
<li>NEJM</li>
<li>Cocktail approach - a single dose PK study - old fashion clinical pharmacology approach? -</li>
<li>Metoprolol and Torsemide PK - heretability</li>
<li>Koryza Genet Med 2016 - comprehensive analysis - ESP project (n=6500) and 1000 genomes project</li>
<li>PNAS 2005 Fraga - Epigenomics and DNA methylation</li>
<li>miRNA, methylation, histone modification(acetylation)</li>
<li>CPT 2016, Fisel, Schaeffeler, Schwab - DNA methylation and its impact on disease pathophysioloy and drug therapy</li>
<li>Heatmap - ADME genes - SLC transporters</li>
</ul>

<h4 id="my-quesion">My Quesion</h4>

<ul>
<li>Can we develop therapeutics which target locus of epigenetic  (Decitabine)- Renal cancer cell - treatment of decitabine - demethylating agents (Specificity?)</li>
<li>Epigenomics</li>
</ul>

<h3 id="16-20-16-50-emerging-roles-of-human-cyp1b1-in-cancer-growth-and-metastasis">16:20~16:50 Emerging roles of human CYP1B1 in cancer growth and metastasis</h3>

<ul>
<li>Speaker: Young-Jin Chun (Chung-Ang University, KOREA)</li>
<li>P450 (CYP1B1)</li>
<li>Estrogen metabolism : E2-&gt;4-OHE2(endogenous mutagen)</li>
<li>ZYC300 cancer vaccine - CYP1B1 DNA Vaccine</li>
<li>Immunity to CYP1B1 -&gt; Clinical benefit</li>
<li>과발현시 - PCNA increased</li>
<li>TMS - specific human CYP1B1 - DMBA-&gt;PPCNA increased, DMBA+TMS-&gt;PBNA back to normal</li>
<li>CYP1B1 -&gt; EMT (ECADHERIN, ZEB1, Vimentin, twist1 ) FUNCTIONAL STUDY , Can we transmembrane migration - cancer progression</li>
<li>SP1 Transctiption factors - Mithramycin A(binding inhibittor) DMBA에의해 증가한 에스피1등이 mitA를 억제.</li>
<li>이러한 결과들을 통해서 SP1이 암 증식 chip assay</li>
<li>4OHE는 EMT 촉진된다.</li>
<li>억제 - Mithramycin A</li>
<li>촉진 - DMBA, CYP1B1, SP1, 4OHE</li>
<li>Matrigel, migration -&gt; migration, invasion</li>
</ul>

<p>####
1B1에 의해 대사되는 irinotecan - 알수가 없다. Tumor 조직을 갖고 enzyme activity 측정전에.
active metabolism
2D6는 steroid</p>

<h3 id="16-50-17-20-omics-for-precision-medicine-clinical-implementation-in-oncology">16:50~17:20 omics for precision Medicine : Clinical Implementation in oncology</h3>

<ul>
<li>Speaker: Kyu-pyo Kim (University of Ulsan College of Medicine, KOREA)</li>
<li>effects are not immediate / severe adverse effects / narrow therapeutic window</li>
<li>UGT1A1 genotypes - different enzyme activities , Irinotecan</li>
<li>Irinotecan -&gt; practical decision making - not reached.</li>
<li>genotype information - strong enough?</li>
<li>neutropenia, diarrhea</li>
<li>mutations are abundant - mutational loading (high- melanoma, lung sq cel carcinoma)</li>
<li>Point mutations, copy # variation -&gt; omics + NGS -&gt; clinical interpretation -&gt; clinical decision making</li>
<li>Ca Cancer J Clin 2016 - 1 month TIME IS IMPORTANT FOR PATIENTS.</li>
<li>Issues : Forces or hurdles - COSTS - volume of patients/turnaround time/Central testing/Quality control</li>
<li>NCI-Match - somatic mutation - Oncomine Comprehensive Assay Gene List - How to report???</li>
<li>KRAS A146 mutation in CRC -&gt; CTX guideline - clinical trial</li>
<li>CPCM - KCSG 11th methodology -</li>
<li>Transition : from research to practice - CLIA (23andMe)</li>
<li>NGS 임상검사실 인증제도 추진중임.</li>
<li>Summary - abundance of information is helpting us</li>
<li>there are many hurdles</li>
<li>multi-disciplinary efforts are needed.</li>
</ul>

<h2 id="17-20-17-30-인정의-자격증-수여식-ji-young-park-kscpt">17:20~17:30  인정의 자격증 수여식 Ji-Young Park (KSCPT)</h2>

<h2 id="17-30-closing-remark-jae-gook-shin-chairman-of-kscpt">17:30    Closing Remark  Jae-Gook Shin (Chairman of KSCPT)</h2>

    </div>
  </article>

  


</main>

      <footer class="footer">
        <ul class="footer-links">
          <li>
            <a href="../../../../index.xml" type="application/rss+xml" target="_blank">RSS feed</a>
          </li>
          <li>
            <a href="https://gohugo.io/" class="footer-links-kudos">Made with <img src="../../../../images/hugo-logo.png" width="22" height="22"></a>
          </li>
        </ul>
      </footer>

    </div>
    

    
<script src="../../../../js/math-code.js"></script>
<script type="text/x-mathjax-config">
MathJax.Hub.Config({
  tex2jax: {
    inlineMath: [['$','$'], ['\\(','\\)']],
    processEscapes: true
  }
});
</script>
<script async src="//cdn.bootcss.com/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML"></script>


    
  </body>
</html>

